Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial

The Lancet

Volumn 386, Issue 10008, 2015, Pages 2059-2068

  Williams, Bryan ^a   Macdonald, Thomas M ^b   Morant, Steve ^b   Webb, David J ^c   Sever, Peter ^d   McInnes, Gordon ^e   Ford, Ian ^f   Cruickshank, J Kennedy ^g   Caulfield, Mark J ^h   Salsbury, Jackie ⁱ   Mackenzie, Isla ^b   Padmanabhan, Sandosh ^e   Brown, Morris J ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CREATININE; DOXAZOSIN; POTASSIUM; SODIUM; SPIRONOLACTONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COMPUTER SYSTEM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HOME SYSTOLIC BLOOD PRESSURE; HUMAN; HYPERKALEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; COMPARATIVE STUDY; HYPERTENSION; MIDDLE AGED; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; BISOPROLOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84947863698     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00257-3     Document Type: Article

References (22)

1. A Myat, SR Redwood, AC Qureshi, JA Spertus, B Williams Resistant hypertension BMJ 345 2012 e7473
2. B Williams Resistant hypertension: an unmet treatment need Lancet 374 2009 1296 1298
3. D Achelrod, U Wenzel, S Frey Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations Am J Hypertens 28 2015 355 361
4. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and Task Force for the management of arterial hypertension of the European Society of Cardiology Blood Press 22 2013 193 278
5. DA Calhoun, D Jones, S Textor et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
6. T Krause, K Lovibond, M Caulfield et al. Management of hypertension: summary of NICE guidance BMJ 343 2011 d4891
7. NICE NICE hypertension guideline CG127 https://www.nice.org.uk/guidance/cg127 (accessed May 26, 2015).
8. E Pimenta, KK Gaddam, S Oparil et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial Hypertension 54 2009 475 481
9. SJ Taler, SC Textor, JE Augustine Resistant hypertension: comparing hemodynamic management to specialist care Hypertension 39 2002 982 988
10. MJ Brown Renin: friend or foe? Heart 93 2007 1026 1033
11. K Dahal, S Kunwar, J Rijal et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomised and non-randomised studies Am J Hypertens 2015 10.1093/ajh/hpv031 published online March 23.
12. B Williams, TM MacDonald, M Caulfield et al. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension BMJ Open 5 2015 e008951
13. A Morganti A comparative study of inter and intra-laboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin J Hypertens 28 2010 1307 1312
14. J Václavík, R Sedlák, M Plachy et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 2011 1069 1075
15. CS Oxlund, JE Henriksen, L Tarnow, K Schousboe, J Gram, IA Jacobsen Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial J Hypertens 31 2013 2094 2102
16. SJ Hood, KP Taylor, MJ Ashby, MJ Brown The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio Circulation 116 2007 268 275
17. EA Azizan, H Poulsen, P Tuluc et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension Nat Genet 45 2013 1055 1060
18. L Wei, AD Struthers, T Fahey, AD Watson, TM MacDonald Spironolactone use and renal toxicity: population based longitudinal analysis BMJ 340 2010 c1768
19. N Chapman, J Dobson, S Wilson et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 2007 839 845
20. MK Nishizaka, MA Zaman, DA Calhoun Efficacy of low-dose spironolactone in subjects with resistant hypertension Am J Hypertens 16 2003 925 930
21. M Tomaszewski, C White, P Patel et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LCMS/MS) urine analysis Heart 100 2014 855 861
22. S Kjeldsen, RD Feldman, L Lisheng et al. Updated national and international hypertension guidelines: a review of current recommendations Drugs 74 2014 2033 2051